Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
Revenue of Zynerba Pharmaceuticals, Inc. (ZYNE)
Revenue in 2022 (TTM): $
According to Zynerba Pharmaceuticals, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Zynerba Pharmaceuticals, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2022 | $ | $ | $-34,620,414 | $-35,035,806 | $-34,820,072 |
| 2021 | $ | $ | $-36,210,709 | $-37,309,024 | $-37,600,518 |
| 2020 | $ | $ | $-52,544,261 | $-51,336,831 | $-50,404,085 |
| 2019 | $ | $ | $-34,173,899 | $-32,943,583 | $-31,433,477 |
| 2018 | $86 K | $86 K | $-39,923,162 | $-39,911,175 | $-39,911,175 |
| 2017 | $7.25 K | $7.25 K | $-33,114,160 | $-32,012,304 | $-32,012,304 |
| 2016 | $7.25 K | $7.25 K | $-22,918,984 | $-23,416,050 | $-23,388,507 |
| 2015 | $278.9 K | $278.9 K | $-12,505,132 | $-12,523,807 | $-12,551,350 |
| 2014 | $810.01 K | $810.01 K | $-5,640,670 | $-5,669,577 | $-5,669,577 |
| 2013 | $943.9 K | $943.9 K | $-585,047 | $-636,790 | $-636,790 |